Lead researcher, Jonathan Chow said, “This is our third study and the culmination of 15 months of work looking at aspirin use in hospitalized Covid-19 patients. We continue to find that aspirin use is associated with improved outcomes and lower rates of death in hospitalized patients.
What’s more, it’s low cost and readily available, which is important in parts of the world where more expensive therapeutics might not be as accessible.”
Researchers found a 1.6% reduction in mortality when aspirin was given within the first day of hospitalization in patients with moderate disease severity and that patients were less prone to forming blood clots.
They also found that elderly patients and patients with one or more comorbidities especially benefit from early aspirin therapy.
“This research is vital to providing physicians and patients effective and accessible COVID-19 treatments to help reduce in-hospital mortality rates and help people recover from this potentially devastating disease.”